Evaluation of Dual Time Point Imaging 18F-FDG PET/CT in Differentiating Malignancy From Benign Gastric Disease

被引:14
|
作者
Cui, Jing [1 ]
Zhao, Panxiong [2 ]
Ren, Zhentai [3 ]
Liu, Baoping [1 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Nucl Med, Zhengzhou, Henan, Peoples R China
[2] Henan Univ, Affiliated Hosp 1, Dept Nucl Med, Kaifeng, Henan, Peoples R China
[3] Zhengzhou Univ, Affiliated Hosp 5, Dept Radiat Oncol, Zhengzhou, Henan, Peoples R China
关键词
F-18-FDG PET; FDG-PET; CANCER; INDEX;
D O I
10.1097/MD.0000000000001356
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To assess the clinical value of dual time point imaging (DTPI) fluorine-18fludeoxyglucose (18F-FDG) positron emission tomography (PET)/CT in differentiating malignancy and benign disease of patients with focally increased gastric uptake.Patients who present focally increased 18F-FDG uptake in gastric wall on conventional PET/CT imaging received delayed imaging. PET/CT scans were acquired at 1 and 2hours (early and delayed imaging) after 18F-FDG injection. The maximum standardized uptake value (SUV) was calculated. The SUVmax of the early and delayed imaging acquisition were signed S1 and S2, respectively. The receiver operating characteristic curve (ROC) of the S1, S2, and the retention index (RI) were drawn to find the best cut-off point value for differential diagnosis. Sensitivity, specificity, Youden index, and the area under the curve (AUC) were calculated, respectively.From September 2010 to May 2015, 74 patients (56 male and 18 female; age of 5712 years; range, 32-86 years) referring for areas of focally increased uptake of 18F-FDG in gastric wall received delayed imaging. The S1 was 5.0 +/- 1.4 (range, 1.9-11.3), and S2 was 5.9 +/- 2.7 (range, 1.0-16.3). The SUVmax were increased in 52 patients in delayed imaging, with 85% (44/52 cases) appeared malignant; decreased in 20 patients, and 90% (18/20 cases) were benign; 2 patients of benign had not changed. The change of SUVmax between malignant and benign was significant difference (t=-5.785, P=0.000).Taking the S1, S2, and RI higher than 4.6%, 5.1%, and 13% as positive diagnostic criteria, the sensitivity were 65.2%,87.0%, and 87.0%, respectively; the specificity were 64.3%, 82.1%, and 89.3%; the Youden index were 0.332, 0.693, and 0.770; AUC were 0.635 (95% confidence intervals (95% CI) 0.507-0.764), 0.873 (95% CI, 0.786-0.961), and 0.923 (95% CI, 0.854-0.992).DTPI is more precise to distinct malignant from benign gastric diseases compared with conventional imaging, and it is readily accessible.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Spectrum of gastric malignancy on 18F-FDG PET/CT: a pictorial essay
    Makis, William
    Ciarallo, Anthony
    Hickeson, Marc
    Rush, Christopher
    Derbekyan, Vilma
    Novales-Diaz, Javier-A
    Laufer, Jerome
    Stern, Jerry
    Lisbona, Robert
    CLINICAL IMAGING, 2012, 36 (05) : 432 - 446
  • [22] Vascular Imaging with 18F-FDG PET/CT: Optimal 18F-FDG Circulation Time?
    Rudd, James H. F.
    Elkhawad, Maysoon
    Fayad, Zahi A.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (09) : 1560 - 1560
  • [23] Limitation of dual time point 18F-FDG PET imaging for differentiating malignant lung carcinoma from pulmonary tuberculosis and granulomatous disease.
    Zhao, J
    Lin, TX
    Guan, HY
    Zuo, TC
    Hua, CF
    Fan, ML
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 135P - 135P
  • [24] The performance of dual time point 18F FDG PET for differentiating malignant and benign processes
    Su, Minggang
    Fan, Qiuping
    Fan, Chenzhong
    Tian, Ye
    Li, Fanglan
    Li, Lin
    Kuang, Anren
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [25] Dual-time point 18F-FDG-PET and PET/CT for Differentiating Benign From Malignant Musculoskeletal Lesions: Opportunities and Limitations
    Parghane, Rahul V.
    Basu, Sandip
    SEMINARS IN NUCLEAR MEDICINE, 2017, 47 (04) : 373 - 391
  • [26] Additional value of dual time point 18F-FDG PET/CT imaging in suspected pulmonary nodules
    Ozkan, E.
    Tari, P.
    Yagci, S.
    Lacin, S.
    Erbay, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S423 - S424
  • [27] PET/CT imaging with 18F-FDG in Castleman disease
    Delgado, A.
    Mesa, J.
    Guayambuco, S.
    Rodriguez, T.
    Fernandez, I.
    Rodeno, E.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2016, 35 (03): : 200 - 201
  • [28] The Value of Dual Time Point 18F-FDG PET/CT Imaging in Differentiating Lymph Node Metastasis From Reactive Hyperplasia in Bladder Urothelial Carcinoma
    Zhou, Xiang
    Lu, Zehua
    Zhang, Ruixue
    Zhang, Ruiyun
    Huang, Gang
    Shi, Kuangyu
    Chen, Haige
    Liu, Jianjun
    ACADEMIC RADIOLOGY, 2024, 31 (08) : 3272 - 3281
  • [29] Primary Benign Intraosseous Meningioma on 18F-FDG PET/CT Mimicking Malignancy
    Kim H.S.
    Kim S.H.
    Kim H.J.
    Kang S.W.
    Kim S.J.
    Lee J.H.
    Hong S.P.
    Cho Y.S.
    Choi J.Y.
    Nuclear Medicine and Molecular Imaging, 2014, 48 (2) : 153 - 156
  • [30] Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma
    Nishiyama, Y
    Yamamoto, Y
    Fukunaga, K
    Kimura, N
    Miki, A
    Sasakawa, Y
    Wakabayashi, H
    Satoh, K
    Ohkawa, M
    JOURNAL OF NUCLEAR MEDICINE, 2006, 47 (04) : 633 - 638